Total RNA was isolated using TRIzol (Invitrogen) and a RNeasy kit (QIAGEN, Duesseldorf, Germany) with DNase I digestion according to the manufacturers' instructions. Reverse transcription reaction was performed using PrimeScriptTM RT reagent Kit (Takara, Tokyo, Japan) and diluted cDNA was used for qRT-PCR analysis using SYBR Premix Ex Taq II Kit (Takara) with the appropriate primers listed in Supplementary Table S4 . For microRNA, stem-loop reverse transcription reactions were performed and the 2 -△ Ct method was used to calculate the relative abundance of RNA genes compared with GAPDH or U6 expression.
Supplementary Table S2 Supplementary Table S3 Supplementary Table S4 was synthesized and subcloned into the pmirGLO vector (Promega, Madison, WI). The 3'untranslated regions (3'-UTR) of TCF4 mRNA containing the intact miR-204/211 recognition sequences were PCR-amplified and subcloned into pmirGLO vector. All PCR products were verified by DNA sequencing. Primers used for plasmid construction are listed in Supplementary Table S4 .
Knockdown by siRNAs siRNAs targeting FAT4, DNMT1, ANXA2, TCF4 were designed and synthesized by Ribo (Guangzhou, China) .
For transient knockdown LncCCAT1, RiboTM LncRNA Smart Silencer (Ribo) was used, which is a pool containing three siRNA and three antisense oligonucleotides ( Supplementary Table S6 ).
Proliferation, migration and Invasion assay
The capacity of cellular proliferation was measured using the Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan) and EdU Cell Proliferation Assay Kit (Ribobio, Guangzhou, China) according to the manufacturer's instructions. The optical density was determined with a microplate reader at a wavelength of 450 nm. To analyze the migration and invasion abilities of cells, transwell migration assay and transwell invasion assay was performed based on published method. For the cell transmembrane migration assay, all the steps were carried out similarly to those in the invasion assay except for the Matrigel (BD Biosciences, San Jose, CA, USA) coating. After incubation at 37˚C for 24 h, the filters were removed. The cells adhering to the lower surface were fixed and stained with Crystal Violet, 10 randomly selected fields in each well were counted. n=3, Magnification was 200×.
Luciferase reporter assay
pmirGLO, pmirGLO-CCAT-WT or pmirGLO-CCAT-MUT (miR-148a/152, miR-204/211) was co-transfected with pre miR-148a/152, pre miR-204/211 mimics or miR-NC into MCF-7 cells by Lipofectamine-mediated gene transfer. pmirGLO, pmirGLO-TCF4-WT or pmirGLO-TCF4-MUT was transfected into MCF-7 cells by lipofectamine-mediated gene transfer. The relative luciferase activity was normalized to Renilla luciferase activity 48h after transfection.
Cell transfection and Lentivirus production
Transfections were performed using the Lipofectamine 2000 kit (Invitrogen) according to the manufacturer's instructions. The double-stranded microRNA mimics and their respective negative control RNAs (GenePharma, Shanghai, China) were transfected into cells at a final concentration of 50 nM. The cells were harvested at 48h after transfection. inhibitor, hsa-miR-152 inhibitor or the control were purchased from (GenePharma). For stable overexpression, the cDNA of LncCCAT1, TCF4 and ANXA2 genes were cloned into the lentiviral expression vector pLVX-IRES-ZsGreen1 (Addgene). To produce lentivirus, HEK-293T cells were co-transfected with the lentiviral vector and packaging vectors psPAX2 and pMD2.G using Lipofectamine 2000 (Invitrogen) according to the manufacturer's guidelines. Infectious lentiviruses were harvested at 48h post transfection and filtered through 0.45μm PVDF filters and the recombinant lentiviruses were concentrated 100-fold by ultracentrifugation (3 h at 50,000 g). The virus-containing pellet was dissolved in DMEM, aliquoted and stored at -80°C. Based on the shRNA sequences provided above, the most effective shRNAs were used for subsequent studies. shRNAs against ANXA2, TCF4 and control hairpins were cloned into pLVX-shRNA2 vector as described above, the virus supernatant was collected and cells were transfected with lentiviral constructs expressing as described above for 24h. The expression of LncCCAT1, ANXA2 and TCF4 in the infected cells was collected for protein and RNA analysis 96h after infection.
Fluorescence in situ hybridization (FISH) and LNA based in situ hybridization (LNA ISH)
Cy3 labeled LncCCAT1 probe was designed and synthesised by (Ribo, Guangzhou, China) . For FISH assay, cells were fixed in 4% formaldehyde and permeabilized with 0.5% Triton X-100 for 5 min, washed with PBS three times and once in 2× SSC buffer. Hybridization was carried out using DNA probe sets at 37°C for 12 h.
Images were obtained with confocal laser microscope (Carl Zeiss, Oberkochen, Germany). In situ hybridization (ISH) was performed by applying the ISH Kit (Boster, Bio-Engineering Company, Wuhan, China). Formalinfixed paraffin embedded (FFPE) tissue slides were deparaffinized and deproteinated. Slides were then prehybridized in prehybridization solution for 2 h at 42 °C and incubated in DIG-labeled probe solution over night at 42°C. After stringent washing, the slides were exposed to a streptavidin-peroxidase reaction system and stained with 3, 3′diaminobenzidine (DAB, ZSGB-BIO, Beijing, China). Hematoxylin (Sigma) was used to counterstain the slides.
The copy number of LncCCAT1 and miRNAs per cell
The standard curves were formulated with limit dilution approaches using LncCCAT1 expressing vector pcDNA3.1-LncCCAT1 and reverse transcribed miR-204/211/148a/152 cDNA as standard templates, and then the exact copy numbers of LncCCAT1 and miR-204/211/148a/152 per cell were calculated according to cell counts and molecular weights. Supplementary Table S1 . LncCCAT1 expression and clinicopathological features in 80 patients with breast cancer. Supplementary Table S2 . Sequences of primers used for qRT-PCR, plasmid construction and ChIP-qPCR. Supplementary Table S3 . Antibodies used for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF) and flow cytometry (FC). Supplementary Table S4 . Sequences of siRNAs and sgRNAs against specific targets. Supplementary Table S4 . Sequences of siRNAs and sgRNAs against specific targets Molecular weight of all the protein： GAPDH: 37 KD; Sox2: 34KD; 4-Oct: 52KD; Nanog: 40KD; ALDH1A1: 56KD; DNMT1: 183KD; TCF4: 
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Supplementary Table S1. LncCCAT1 expression and clinicopathological features in 80 patients with breast cancer
Supplementary Table S2. Sequences of primers used for qRT-PCR, plasmid construction and ChIP-qPCR
Primer names Sequences
Sequences of primers used for qRT-PCR
RNA names Sequences
FAT4-siRNA-1 CTACGAAGATTGGCTGTGA FAT4-siRNA-2 GACGCCAAGTCATCTTAGA FAT4-siRNA-3 GGTCTCGGTTTCAGGTCAA DNMT1-siRNA-1 TCTTTGCATTATAGGCCTC DNMT1-siRNA-2 CAATGAGACTGACATCAAA DNMT1-siRNA-3 GAGGCCTATAATGCAAAGA ANXA2-siRNA-1 CGGCTGTATGACTCCATGA ANXA2-siRNA-2 GACCAACCGCAGCAATGCA ANXA2-siRNA-3 GTCTGTCAAAGCCTATACT TCF4-siRNA-1 GGTCTAGAAATGGAGGACA TCF4-siRNA-2 TGGCTATGCAGGAATGTTG TCF4-siRNA-3 CAGACAGTATAATGGCAAA LncCCAT-siRNA-1 GTAGAAACACTATCACCTA LncCCAT-siRNA-2 CTAGAGAATCACCCAATCT LncCCAT-siRNA-3 GAGTGAGATCAGCGTTATT LncCCAT-ASO-1 TCACCCAATCTACTCCCATT LncCCAT-ASO-2 AAGGTGCCGAGACATGAACT LncCCAT-ASO-3 GTCCCAACTAGCAAGTGCAA sgRNA1 GGTCTTCTCTGCAATCCATCTGGAGCATTCACTGACAACAT sgRNA2 TTAGCTCACCATCTGGAAGAAGGCTGAGTATTCTCTGCAC Figure 2E
